Gamida Cell Ltd. (NASDAQ:GMDA) Receives $15.00 Average Price Target from Analysts

Shares of Gamida Cell Ltd. (NASDAQ:GMDAGet Rating) have earned an average rating of “Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $15.00.

GMDA has been the topic of a number of research analyst reports. Zacks Investment Research lowered Gamida Cell from a “buy” rating to a “hold” rating in a research report on Monday, April 4th. JMP Securities reissued a “buy” rating and issued a $17.00 target price on shares of Gamida Cell in a research report on Tuesday, February 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Gamida Cell in a research report on Wednesday, March 16th.

A number of hedge funds have recently bought and sold shares of GMDA. Stifel Financial Corp bought a new position in Gamida Cell in the fourth quarter valued at approximately $37,000. Bank of New York Mellon Corp bought a new position in Gamida Cell in the third quarter valued at approximately $39,000. Parametric Portfolio Associates LLC boosted its stake in shares of Gamida Cell by 10.7% during the 4th quarter. Parametric Portfolio Associates LLC now owns 32,230 shares of the company’s stock worth $82,000 after acquiring an additional 3,105 shares during the period. GSA Capital Partners LLP bought a new position in shares of Gamida Cell during the 4th quarter worth approximately $83,000. Finally, Phoenix Holdings Ltd. bought a new position in shares of Gamida Cell during the 3rd quarter worth approximately $114,000. Hedge funds and other institutional investors own 53.43% of the company’s stock.

NASDAQ GMDA opened at $3.25 on Friday. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 1.63. The stock’s 50-day moving average is $3.73 and its 200-day moving average is $3.35. Gamida Cell has a one year low of $2.10 and a one year high of $8.15.

Gamida Cell (NASDAQ:GMDAGet Rating) last released its quarterly earnings results on Tuesday, March 15th. The company reported ($0.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.08). During the same period in the prior year, the business earned ($0.68) earnings per share. On average, equities research analysts forecast that Gamida Cell will post -1.18 EPS for the current year.

Gamida Cell Company Profile (Get Rating)

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia.

Featured Stories

Analyst Recommendations for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.